BH-3120

N/A

Report date: 2024/02/01 20:01:00

Base Information

Drug NameBH-3120

Drug Alias NameBH-3120

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsTumor necrosis factor receptor superfamily member 9 agonistsT lymphocytes stimulants +[4]

TargetsProgrammed death-ligand 1Tumor necrosis factor receptor superfamily member 9

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesSouth Korea

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesHanmi Pharmaceutical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesHanmi Pharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A